Science

TGF-β signaling depends on context

TGF-β signaling has roles in normal tissue maintenance and disease. The effect of reducing TGFBR2 depends on cell type and disease setting.

Conceptual receptor signaling within a cellular and tissue environment — Conceptual visualization

TGF-β signaling also maintains normal tissue function

TGF-β signaling participates in immune regulation and tissue homeostasis. Its effects are context-dependent: reducing signaling is not inherently beneficial in every cell or disease stage.

TGFBR2 encodes the type II TGF-β receptor. Together with the type I receptor, it transmits signals through SMAD-dependent and other intracellular pathways.

Supporting literature

Receptor-level signaling

TGF-βExtracellular signal

TGFBR2 + TGFBR1Receptor signaling complex

Cellular responseSMAD and non-canonical pathways

Simplified pathway schematic. Biological effects depend on cellular context.

NVP-13 reduces TGF-β signaling in human cell models

Published experiments in human neural precursor and lung-derived cells show that NVP-13 reduces TGFBR2 RNA and protein and lowers pSMAD2, a marker of TGF-β pathway activity. These findings demonstrate pathway modulation in those cell models; disease-relevant outcomes are the next question.

NVP-13 mechanism and evidence

One target. Two disease contexts

NVP-13 TGFBR2 Testing changes in TGF-β signaling

Conceptual neural, glial and extracellular-matrix environment — Conceptual visualization

01 / NVP-13 · CNS

Neurodegeneration

In human neural precursor cells, NVP-13 reduced TGFBR2 and pSMAD2, a marker of TGF-β signaling. We are investigating its potential in ALS with Qilu Hospital.

Explore the CNS branch

Conceptual transition from organized tissue to dense extracellular-matrix accumulation — Conceptual visualization

02 / NVP-13 · Tissue biology

Fibrosis

Exploring the relationship between persistent TGF-β signaling, matrix accumulation and maladaptive tissue repair. The therapeutic hypothesis requires validation in each disease setting.

Explore the fibrosis branch

Discovery capabilities

Questions guiding discovery research

Conceptual cellular cutaway representing biological discovery — Conceptual visualization

Target discovery & validation

Functional biology and genetic screening connect candidate targets with disease mechanisms.

Molecular therapeutic evaluation

Molecular and cellular assays assess whether an intervention changes its intended target and pathway.

Translational disease biology

Disease models test mechanistic hypotheses and establish the relevance of pharmacological findings.

Biomarker research

Connecting pathway activity with measurable biological responses supports translational decision-making.

Angalbio & JLP Health research

Target discovery in practice

A co-authored study used forward genetics to identify ATP1A1 as a molecular target of periplogenin in prostate-cancer models. It illustrates a discovery approach separate from NVP-13.

2024

Angalbio & JLP Health · Target discovery

The natural compound periplogenin suppresses the growth of prostate carcinoma cells by directly targeting ATP1A1

Zhang X, Pang T, Zhang H, et al.
Scientific Reports 14, 20509 (2024)

Angalbio and JLP Health authors used forward genetics to identify ATP1A1 as a periplogenin target in prostate-cancer models. This is a discovery-platform study, separate from NVP-13.

DOI: 10.1038/s41598-024-71722-7

Confirm the current scope and in-house versus collaborative delivery of discovery capabilities before public launch.